Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis

被引:21
作者
Kim, Ji-Hye [1 ]
Kim, Ae Ri [2 ,3 ,4 ]
Choi, Yun Hui [2 ]
Kim, Aeryun [2 ]
Sohn, Yongsung [5 ]
Woo, Gye-Hyeong [6 ]
Cha, Jeong-Heon [2 ,3 ,4 ,7 ]
Bak, Eun-Jung [2 ]
Yoo, Yun-Jung [2 ,3 ]
机构
[1] Jeonju Kijeon Coll, Dept Dent Hyg, Jeonju, South Korea
[2] Yonsei Univ, Coll Dent, Dept Oral Biol, 134 Sinchon Dong, Seoul 120752, South Korea
[3] Yonsei Univ, Grad Sch, Dept Appl Life Sci, Seoul, South Korea
[4] Yonsei Univ, Coll Dent, PLUS Project BK21, Seoul, South Korea
[5] DONG A Pharm, Yongin, Gyeonggi Do, South Korea
[6] Semyung Univ, Dept Clin Lab Sci, Jecheon, South Korea
[7] Guangzhou Med Univ, Stomatol Hosp, Guangzhou Inst Oral Dis, Microbiol & Mol Biol,Key Lab Oral Med, Guangzhou, Guangdong, Peoples R China
来源
JOURNAL OF TRANSLATIONAL MEDICINE | 2018年 / 16卷
基金
新加坡国家研究基金会;
关键词
PTH; Diabetes; Periodontitis; Alveolar bone formation; PARATHYROID-HORMONE; SCLEROSTIN; OSTEOCYTES; MECHANISM; MICE;
D O I
10.1186/s12967-018-1438-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Periodontitis is an infectious disease that manifests as alveolar bone loss surrounding the roots of teeth. Diabetes aggravates periodontitis-induced alveolar bone loss via suppression of bone formation. Intermittent parathyroid hormone (PTH) administration displays an anabolic effect on bone. In this study, we investigated the effect of intermittent PTH administration on alveolar bone loss in type 1 diabetic rats with periodontitis. Methods: Rats were divided into control (C), periodontitis (P), periodontitis treated with PTH (P + PTH), diabetes with periodontitis (DP), and diabetes with periodontitis treated with PTH (DP + PTH) groups. To induce type 1 diabetes, rats were injected with streptozotocin and periodontitis was induced bilaterally by applying ligatures to the mandibular first molars for 30 days. During the experimental period, the P + PTH and DP + PTH groups were subcutaneously injected with PTH (40 mu g/kg) three times per week, whereas the C, P, and DP groups were injected with citrate buffer. To observe the mineralization of the alveolar bone, the DP and DP + PTH groups were injected with calcein on days 10 and 27, and with alizarin red on day 20. Thirty days after ligation, histological findings and fluorescence labeling were analyzed in the furcations of the mandibular first molars. Sclerostin-positive osteocytes were assessed by immunohistochemical analyses. Results: The DP groups had smaller areas of alveolar bone than the other groups, and the DP + PTH group had a larger alveolar bone area than the DP group. The DP group had less osteoid formation than the C group, whereas the DP + PTH had greater osteoid formation than the DP group. Fluorescence labeling results revealed that the DP + PTH group had more mineral deposition on the alveolar bone than the DP group. The DP + PTH group exhibited lower percentage of sclerostin-positive osteocytes in alveolar bone than the DP group. Conclusions: Intermittent PTH administration diminishes alveolar bone loss and sclerostin expression in osteocytes, but increases osteoid formation and mineralization, suggesting that intermittent PTH administration attenuates diabetes-aggravated alveolar bone loss by the induction of bone formation. PTH-induced bone formation may be related to the regulation of osteocytic sclerostin expression in type 1 diabetic rats with periodontitis.
引用
收藏
页数:7
相关论文
共 23 条
  • [1] Therapeutic effect of a topical CCR2 antagonist on induced alveolar bone loss in mice
    Barros, S. P.
    Arce, R. M.
    Galloway, P.
    Lawter, R.
    Offenbacher, S.
    [J]. JOURNAL OF PERIODONTAL RESEARCH, 2011, 46 (02) : 246 - 251
  • [2] Parathyroid hormone protects against periodontitis-associated bone loss
    Barros, SP
    Silva, MAD
    Somerman, MJ
    Nociti, FH
    [J]. JOURNAL OF DENTAL RESEARCH, 2003, 82 (10) : 791 - 795
  • [3] Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis
    Bellido, T
    Ali, AA
    Gubrij, I
    Plotkin, LI
    Fu, Q
    O'Brien, CA
    Manolagas, SC
    Jilka, RL
    [J]. ENDOCRINOLOGY, 2005, 146 (11) : 4577 - 4583
  • [4] Effects of PTH on osteocyte function
    Bellido, Teresita
    Saini, Vaibhav
    Pajevic, Paola Divieti
    [J]. BONE, 2013, 54 (02) : 250 - 257
  • [5] Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis
    Chen, Hui
    Xu, Xinchen
    Liu, Min
    Zhang, Wen
    Ke, Hua-zhu
    Qin, An
    Tang, Tingting
    Lu, Eryi
    [J]. BONE, 2015, 76 : 141 - 148
  • [6] Role and mechanism of action of sclerostin in bone
    Delgado-Calle, Jesus
    Sato, Amy Y.
    Bellido, Teresita
    [J]. BONE, 2017, 96 : 29 - 37
  • [7] The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats
    Dobnig, H
    Turner, RT
    [J]. ENDOCRINOLOGY, 1997, 138 (11) : 4607 - 4612
  • [8] Inflammation and Uncoupling as Mechanisms of Periodontal Bone Loss
    Graves, D. T.
    Li, J.
    Cochran, D. L.
    [J]. JOURNAL OF DENTAL RESEARCH, 2011, 90 (02) : 143 - 153
  • [9] Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
    Jilka, Robert L.
    [J]. BONE, 2007, 40 (06) : 1434 - 1446
  • [10] SOST is a target gene for PTH in bone
    Keller, H
    Kneissel, M
    [J]. BONE, 2005, 37 (02) : 148 - 158